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Abstract
The cysteinyl leukotrienes (cysLTs) and the peptide hormone endothelin (ET)-1 are potent bronchoconstrictor sub-
stances, and thesemediators are also claimed to be implicated in the development of eosinophilic airway inflammation.
Inthepresent study, wehaveinvestigatedthe effectofthe cysLT1receptor antagonistmontelukastonthe developmentof
aneosinophilic airwayinflammation 24 hafterintratracheal Sephadex (SDX) provocationinrats.Furthermore, theeffect
ofmontelukasttreatmentonthegenerationof ET-1andotherpro-inflammatorymediatorshasbeen studied.Theinflam-
matory response was significantly reduced in the animals receiving SDX+montelukast compared to animals receiving
solely SDX, as evaluated by a decrease in bronchoalveolar lavage fluid total cell count (10.371.2 vs.18.571.8104ml1,
Po0.001), number of eosinophils (299.7743.8 vs. 577.6746.6102ml1, Po0.001), and lymphocytes (116.8720 vs.
222.0734.8 102ml1, Po0.05), as well as the degree of tissue inflammation (Po0.05).Montelukast also inhibited the
increase in the concentration of the pro-inflammatory mediators ET-1 (28.577.5 vs. 40.977.3 pgml1, Po0.05) and
interferon (IFN)-g (4.372.2 vs.15.678.7 pgml1, Po0.05), but not tumor necrosis factor-g or interleukin-8. In sum-
mary, treatment with the cysLT1receptor antagonistmontelukast reduced the inflammatory response during develop-
ment of an eosinophilic airway inflammation, possibly by inhibiting the release of pro-inflammatorymediators like ET-1
and IFN-g.r2002 Elsevier Science Ltd.Allrights reserved
Available online athttp://www.sciencedirect.com
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The cysteinyl leukotrienes (cysLTs) (LTC4/D4/E4) and the
peptide hormone endothelin (ET)-1are potent broncho-
constrictor substances (1^3). In addition to the broncho-
constrictor properties, these mediators seem to be
implicated in the development of the eosinophilic airway
in£ammation (4^6), which is a key feature of asthmatic
airways.CysLTs have been shown to facilitate the migra-
tion of eosinophilic granulocytes in vitro (7), and aeroso-
lized cysLTs elicit in£ux of eosinophils into guinea pig
airways in vivo(4). Moreover, LTD4 challenge has beenReceived1October 2001, accepted in revised form 21March 2002
Correspondence should be addressed to: Finn Finsnes,MD, PhD,
Skagen18, 4006 Stavanger,Norway.Fax: +47 5154 84 89; E-mail:
¢nn@¢nsnes.noreported to increase the percentage of eosinophils in
sputum from asthmatic patients(8).
Themechanismby which the cysLTs promote in£ux of
in£ammatorycells has notbeen fullyelucidated, butboth
a direct chemotactic e¡ect andrecruitmentof in£amma-
tory cells by promoting the generation of other chemo-
tactic mediators are possible mechanisms. During the
development of an experimental eosinophilic airway in-
£ammation, Namovic et al. found that the in£ux of eosi-
nophils into the airways was preceded by an increase in
the level of cysLTs (9). In comparable studies, also employ-
ing themodel of Sephadex (SDX) provocation in rats, we
have found a similar patternwith regard to ET-1 (10).The
rapid generation of both cysLTs and ET-1 is consistent
with a hypothesis that these mediators may play impor-
tant roles in the initiation of an eosinophilic airway
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might in fact stimulate the generation of the pro-in£am-
matory mediator ET-1 (11). Based on these ¢ndings, and
studies indicating an anti-in£ammatory e¡ect of cysLT1-
inhibitors on eosinophilic airway in£ammations (12,13),
we hypothesized that cysLT1 receptor antagonists may
inhibit the generation of the pro-in£ammatorymediator
ET-1.Wehavepreviously shown that inhibition of ET-1 ac-
tivity reduces the in£ammatory response in an experi-
mental eosinophilic airway in£ammation (5).
During the last years, a number of LT-inhibitors have
been developed. In clinical practice, the cysLT1 receptor
antagonists have gained most interest. An inhibitory ef-
fect on bronchoconstriction in asthmatics has been
documented (14^17). Evidence for an anti-in£ammatory
e¡ect invivo is, however, limited.To study the anti-in£am-
matory properties of the cysLT1 receptor antagonist
montelukast, we induced an eosinophilic airway in£am-
mation in rats by intratracheal instillation of SDX. SDXis
a dextran to which some rat strains are naturally sensi-
tized, and bronchial or intratracheal provocation with
these particles promotes an allergic eosinophilic in£am-
mation (18). One group of animals were treated with
montelukast prior to the bronchial challenge, while the
control group received saline.The e¡ect of montelukast
treatment on the in£ammatory response in bronchoal-
veolar lavage £uid (BALF) and lung tissue was studied.
In addition, the level of ET-1 in the BALF was measured,
as was the concentration of the pro-in£ammatorymed-
iators tumor necrosis factor (TNF)-a, interleukin (IL)-8
and interferon (IFN)-g, as we previously have observed
an increase of these cytokines following SDX provoca-
tion of rats (19).
METHODS
Experimental procedure
MaleWistar rats aged12 weeks with an average weight
of 320 g were used in the study. The experiments were
approved by the Norwegian Ethics Committee for Ani-
mal Research, and performed according to the NIH
guidelines for theuse of experimental animals. SDX solu-
tion (5mgml1) (G-200 Super¢ne, PharmaciaUpjohn,
Uppsala, Sweden) dissolved in phosphate-bu¡ered saline
(PBS) or PBS alonewas given in a volume of 0.3ml intra-
tracheally to rats pretreated with either saline or mon-
telukast (n=12 in each group). A dose of 2mgkg1body
weight of the highly selective (20) cysLT1 receptor an-
tagonists montelukast (Merck Frosst, Canada Inc.) was
chosen according to themanufacturer and administered
orally 1h prior to provocation, and repeated after 8 and
16h. Pilot studies revealed no e¡ect of montelukast
treatment on the levels of ET-1, TNF-a, IL-8 and IFN-g
in rats receivng intratracheal PBS instead of SDX.
Bronchoalveolar lavage was performed by instillation of3+2+2ml PBS in the right stem bronchus, distal to the
upper lobe, and the procedure was repeated on the left
side.The lavage £uid was collected into prechilled tubes
containing EDTA and kept on ice until centrifuged at
800g for10min. at 41C.
Cell pro¢le in BALF and tissue in£ammation
Total cell recovery in BALF was counted in a Bˇrker he-
mocytometer, the pro¢le of the in£ammatory cells was
evaluated on Di¡-Quicks (Baxter Diagnostics AG, Dˇ-
dingen, Switzerland)-stained slides, and at least 400 non-
epithelial cells were determined.Lung and airway tissues
were embedded in para⁄n, and hematoxylin^ eosin-
stained histological sections (5mm) were screened by
two observers in a blindedmanner.The in£ammatory re-
sponse was assessed in tissues from all animals. Twenty
regions were examined and the in£ammatory response
graded as strong (score 3, 4300 in£ammatory cells),
moderate (score 2, 75^300 in£ammatory cells), weak
(score1,o75 in£ammatory cells), or absent (score 0).
Biochemical analyses
ET-1 was determined using a radioimmuno-linked en-
dothelin 1^21 speci¢c [125I] assay system (RPA 555) from
Amersham Pharmacia Biotech International, Cardi¡,
U.K.Prior to ET-1analysis, sampleswere extractedindu-
plicate from 2ml BALF. The BALF was added to acetic
acid on Sep-Pak C18 cartridges (Millipore Corp., Milford,
MA, U.S.A.), which were prewashed with ethanol and
acetic acid. The extract was freeze dried and dissolved
in borate bu¡er. The ET-1 assay has a limit of detection
equivalent to1.6 pgml1. For the samples with ET-1 con-
centrations below this limit, the values were set to
1.6 pgml1. TNF-a was measured using a rat-speci¢c
sandwich enzyme-linked immunosorbent assay (ELISA)
(Factor-Test-Xs, Genzyme Corporation, Cambridge,
MA,U.S.A.).Valuesbelow the detection limitof this assay
system (10pgml1) were consequently set to 10pgml1.
IFN-g was analyzed using a rat speci¢c ELISA (Cytosc-
reens, BioSource International, Camarillo, CA, USA)
and IL-8 (CINC/gro) was measured with Panatests Rat
IL-8 ELISA (PanapharmLaboratories,Kumamoto, Japan).
All measurements were performed in duplicate, and va-
lues are given as means. For TNF-a, IL-8, and IFN-g as-
says, the BALF was concentrated ten-fold prior to
analysis.The BALF was concentrated using Minicon cells
(Amion Division,WR.Grace & Co., Beverly,MA,U.S.A.).
Results are given as pgml1unconcentrated BALF.
Statistical analysis
All values are expressed asmeans7SEM. Statistical ana-
lyseswereperformedusing scienti¢c statistical software
MONTELUKAST INEXPERIMENTALEOSINOPHILICAIRWAYINFLAMMATION 903(SigmaStat version 2.0, Jandel Scienti¢c GmbH, Ekrath,
Germany). The groups were compared using Kruskal^
Wallis one way analysis of variance on ranks, followed
by a multiple comparisons procedure vs controls using
Dunn’s method. A P-value of less than 0.05 was consid-
ered statistically signi¢cant.
RESULTS
Cell pro¢le in BALF and tissue in£ammation
The SDX-induced increase in BALF total cell count was
strongly inhibited by treatment with montelukast
(10.371.2 vs controls; 18.571.8104ml1, Po0.001) (Fig.
1(A).The numbers of eosinophils and lymphocytes were
also signi¢cantly lower in the SDX+montelukast-trea-
ted animals than in the animals receiving solely SDX (eo-
sinophils; 299.7743.8 vs 577.6746.6102ml1, Po0.001,
and lymphocytes; 116.8720 vs. 222.0734.8102ml1,
Po0.05) (Figs. 1(B) and (C). No signi¢cant inhibition by
montelukast could be observedwith regard to the num-
ber of neutrophils andmacrophages (Figs.1(D) and (E).
The histological evaluation of lung and airway sections
following SDX-provocation of the animals revealed a
pronounced in£ammation peribronchially and surround-
ing the SDXparticles, dominatedbyeosinophils, neutro-
phils and macrophages. Treatment with montelukast
resulted in a moderate decrease in the extent of in£am-
mation in the tissues (in£ammatory score; 1.9270.08 vs
2.1470.05, Po0.05) (Fig. 2).
Mediators in BALF
After 24h, a signi¢cant increase in the concentration of
both ET-1, IFN-g TNF-a, and IL-8 was observed in the
SDX-treated animals, compared to controls (Fig. 3).
Treatment with montelukast prior to SDX provocation
resulted in 30% decrease in the BALF level of ET-1
(Po0.05) (Fig. 3(A)) and a 72% decrease in IFN-g
(Po0.05) (Fig. 3(B)), compared to the animals receiving
solely SDX (Fig. 3). The reduction in the concentration
of TNF-a (30% and IL-8 (60%)) did not reach statistical
signi¢cance (Figs 3(C) and (D)).
DISCUSSION
The SDX-induced in£ammatory response was reduced
by pretreatment of the animals with the cysLT1receptor
blocker montelukast.We observed a decrease in BALF
total cell count and in thenumberof eosinophils and lym-
phocytes, as well as a reduction in the degree of tissue
in£ammation. In addition, treatment with montelukast
signi¢cantly inhibited the SDX-induced increase in the
concentration of the pro-in£ammatory mediators ET-1
and IFN-g.Eosinophils and lymphocytes are the two cell lines
most strongly associated with bronchial asthma (21).
Therefore, it is interesting that the observed anti-in-
£ammatory e¡ect of montelukast seems to be related
to a decrease in the number of both these cell types.
With regard to eosinophils, Diamant et al. (17) did not
observe an inhibitory e¡ect ofmontelukast on the in£ux
of eosinophils into the airways of asthmatic patients
after allergen challenge, however, that study was not
speci¢cally designed or powered to evaluate sputum eo-
sinophils.On the other hand, Pizzichini et al. (12) found a
reduced percentage of eosinophils in induced sputum
from asthma patients during montelukast treatment,
and, in ovalbumin-sensitized rats, montelukast has also
been shown to inhibit the in£ux of eosinophils into the
airways(13). The current study also examined the e¡ect
of montelukast treatment on the number of BALF lym-
phocytes, since these cells also play an important role in
the asthmatic airway in£ammation (21).The inhibitory ef-
fect ofmontelukast on the in£uxof lymphocytes, in addi-
tion to a decrease in the number of eosinophils, is
interesting. Using another cysLT1 receptor antagonist,
za¢rlukast, similar ¢ndings of a reduced number of lym-
phocytes have been shown following segmental allergen
challenge in asthmatics (22), but to our knowledge, re-
duction in the number of lymphocytes has not been re-
ported after treatment withmontelukast.
Themechanismsby which cysLT1receptor antagonists
inhibit the in£ux of eosinophils and lymphocytes have
not been elucidated. A direct chemotactic e¡ect of
cysLTs on these cells may explain the rapid in£ux of leu-
kocytes into the airways (8,23).Thus, blocking cysLT1 re-
ceptors would inhibit that mechanism. On the other
hand, LTs might promote in£ux of in£ammatory cells
through the release of other pro-in£ammatory media-
tors. One study could show a blunted TNF-a release in
BALF from allergen-challenged asthmatics pretreated
with za¢rlukast (22), and in vitro, pranlukast inhibits the
IL-4 and IL-5 response from isolated mononuclear cells
(24). Finally, montelukast has recently been shown to re-
duce the number of IL-5 mRNA expressing cells after
antigen stimulation inrats (13).Thepresent study demon-
strates thatmontelukast signi¢cantly inhibited the SDX-
induced ET-1 release in BALF. This has previously not
been reported. During the development of an SDX-in-
duced airway in£ammation, LTs in BALF are generated
prior to the eosinophilic in£ammatory response (19)
and immediately before the generation of ET-1 (19). Since
LTs seem to be generated before ET-1, and cysLTs have
been shown to stimulate ET-1release in vitro (11), it is pos-
sible that treatment with a cysLT1 receptor antagonist
might in£uence the generation of ET-1 and thereby re-
duce the chemotactic e¡ect of this peptide in vivo. This
hypothesis is concordant with the current results, since
treatment with the cysLT1receptor antagonist montelu-
kast inhibits the release of ET-1, as well as the in£ux of
FIG. 1. Cell pro¢le in BALF of rats evaluated 24 h after intratracheal provocation with saline (controls) or SDX, or SDX following
montelukasttreatment (n=12 in each group).Values are given asmeans7SEM.
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peptide ET-1 is associated with the development of air-
way in£ammation (5,6,10,25), and blocking of ET-recep-
tors results in a decreased in£ux of both eosinophils and
lymphocytes, a pattern similar to what is seen during
treatment with montelukast. We do not believe that
the reduced levels of ET-1is a result of a reduced number
of in£ammatory cells after cysLT1 receptor antagonism,
since ET-1 is producedmainly in bronchial epithelial cells
and in macrophages (10). In previous studies, as well, wehave observed changes in ET-1levels in BALF without al-
terations in the number of macrophages (5,10).
The IFN-g response in the present study was also in-
hibited by the treatment withmontelukast, possibly due
to reduction of the number of lymphocytes, since IFN-g
is mainly produced by these cells (26). Another possibi-
lity is that the IFN-g release is blunted due to decreased
ET-1 concentration, since decreased levels of IFN-g has
been demonstrated after treatmentwith an ETreceptor
antagonist in the SDX model (19). Importantly, IFN-g
MONTELUKAST INEXPERIMENTALEOSINOPHILICAIRWAYINFLAMMATION 905upregulates monocyte and macrophage functions (27)
and is also a potent activator of eosinophilic granulocytes
(26).The concentration of TNF-a, which may be synthe-
sised from a variety of cells including airway epithelialFIG. 2. Evaluation of airway tissue in£ammation in rats evalu-
ated 24 h after i.t. provocationwith saline (controls) or SDX, or
SDX followingmontelukasttreatment.
FIG. 3. Mediatorsin BALFofratsevaluated 24 h afterintratrachea
telukasttreatment (n=12 in each group).Values are given asmeans7cells, macrophages, mast cells and eosinophils (28),
was not signi¢cantly reduced bymontelukast treatment
in the current study, neither was the concentration
of IL-8. However, there was a clear trend in the
direction of reduced levels of these cytokines in BALF,
as well.
In conclusion, treatment with the cysLT1 receptor an-
tagonistmontelukast signi¢cantly reduced the in£amma-
tory response in an SDX-induced airway in£ammation in
rats, as evaluated by a decrease in BALF total cell count,
the number of eosinophils and lymphocytes, as well as
the degree of tissue in£ammation. The generation of
ET-1 and IFN-g in BALF was also reduced by monte-
lukast treatment, indicating one possible mechanism
for the anti-in£ammatory e¡ect of this cysLT1 receptor
antagonist.
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